Alcobra (ADHD) Announces New Findings On Diminished Abuse Potential Of Its Proprietary Drug Candidate, MG01CI  
11/22/2013 9:27:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today the results from a preclinical abuse liability study that evaluated the potential reinforcing effects of Metadoxine (i.e. its ability to produce psychological dependence or craving) using a well-established self-administration procedure in methylphenidate-trained rats. Data from this study affirm that Metadoxine has substantially less potential to be a recreationally abused drug than methylphenidate, a common stimulant ADHD medication.

Help employers find you! Check out all the jobs and post your resume.